Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2025

The programmed death (PD)-1 non-small cell lung cancer market size has grown strongly in recent years. It will grow from $25.23 billion in 2024 to $27.5 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth during the historical period can be attributed to the rising prevalence of non-small cell lung cancer, increased adoption of immunotherapy in developed countries, greater awareness of cancer screening, more approvals for monoclonal antibodies, and higher healthcare spending.

The programmed death (PD)-1 non-small cell lung cancer market size is expected to see strong growth in the next few years. It will grow to $38.26 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The projected growth in the forecast period can be attributed to increasing investments in cancer-specific infrastructure, expanding patient access to biologics in emerging markets, a growing global geriatric population, enhanced reimbursement support for immunotherapies, and rising clinical success rates of PD-1 inhibitors. Key trends expected during this period include technological advancements in biomarker testing, progress in combination immunotherapy protocols, investments in personalized treatment strategies, ongoing research and development of novel PD-1 inhibitors, and innovations in immune checkpoint blockade mechanisms.

The growing adoption of personalized treatments is expected to drive growth in the programmed death (PD)-1 non-small cell lung cancer market. Personalized treatments involve medical approaches customized to an individual’s genetic makeup, lifestyle, and specific disease traits to achieve more targeted and effective results. The increased demand for personalized therapies is fueled by the wider availability of genomic profiling and biomarker testing, which help identify particular mutations and biological markers, enabling clinicians to select treatments likely to be more effective for each patient. Personalized treatments assist programmed death (PD)-1 non-small cell lung cancer (NSCLC) care by tailoring therapies according to a patient’s genetic profile, tumor features, and immune response. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, compared to six in 2022. Thus, the increasing use of personalized treatments is contributing to the expansion of the PD-1 non-small cell lung cancer market.

Key companies in the programmed death (PD)-1 non-small cell lung cancer market are conducting clinical trials on innovative therapies, such as monotherapy, to enhance patient outcomes. Monotherapy refers to a treatment strategy that employs a single drug or therapy to address a disease or condition. For instance, in March 2025, Akeso, Inc., a China-based biopharmaceutical firm, announced positive Phase III HARMONi-2 trial results evaluating Ivonescimab (AK112) combined with chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC). The trial achieved its primary endpoint by significantly prolonging progression-free survival compared to pembrolizumab, showcasing the therapeutic potential of this dual-targeted bispecific antibody.

In February 2025, BioNTech SE, a Germany-based biotechnology company, acquired Biotheus Inc. for an undisclosed sum. This acquisition provided BioNTech access to Biotheus’s lead candidate, PM8002, a bispecific antibody targeting PD-L1 and vascular endothelial growth factor (VEGF)-A, which is in late-stage clinical trials for non-small cell lung cancer and other solid tumors. Biotheus Inc. is a China-based company specializing in the development of multispecific biologics and immuno-oncology therapies for cancer treatment, including PD-1 therapies for NSCLC.

Major players in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., MacroGenics Inc., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., and Shanghai Henlius Biotech Inc.

North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in programmed death-1 (PD-1) non-small cell lung cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the programmed death-1 (PD-1) non-small cell lung cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The programmed death-1 (PD-1) non-small cell lung cancer market consists of revenues earned by entities by providing services such as clinical oncology services for immunotherapy administration, companion diagnostic testing, and comprehensive patient support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The programmed death-1 (PD-1) non-small cell lung cancer market also includes sales of pembrolizumab (Keytruda), nivolumab (Opdivo), and cemiplimab (Libtayo). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The programmed death (PD)-1 non-small cell lung cancer market research report is one of a series of new reports that provides programmed death (PD)-1 non-small cell lung cancer market statistics, including programmed death (PD)-1 non-small cell lung cancer industry global market size, regional shares, competitors with a programmed death (PD)-1 non-small cell lung cancer market share, detailed programmed death (PD)-1 non-small cell lung cancer market segments, market trends and opportunities, and any further data you may need to thrive in the programmed death (PD)-1 non-small cell lung cancer industry. This programmed death (PD)-1 non-small cell lung cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Programmed death-1 (PD-1) non-small cell lung cancer (NSCLC) is a type of lung cancer in which the tumor avoids immune system detection by utilizing the PD-1 pathway, an important immune checkpoint. PD-1 is a receptor found on T cells that, when bound by its ligands (PD-L1 or PD-L2), dampens immune responses to protect tissues from damage. In NSCLC, tumors frequently overexpress PD-L1, allowing them to evade the immune system and promote cancer growth.

The main categories in the programmed death (PD)-1 non-small cell lung cancer market include monotherapy and combination therapy. Monotherapy involves treating the disease with a single drug, without combining it with other treatments. It is applied across various therapy lines, including first-line, second-line, and later stages, and is used by diverse end users such as hospitals, specialized cancer centers, academic and research institutions, and others.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.